Comparison of Longer-term (5 Year+) Outcomes (Survival) of Smokers, Ex-smokers, Never Smoker and Quitters (LungCast2)

August 11, 2025 updated by: Hywel Dda Health Board

Comparison of Longer Term Outcomes Following the LungCast "Smoking Cessation in Lung Cancer Study". Revisiting the Original LungCast Research Cohort to Look at Longer-term Outcomes (5+ Years) in Newly Diagnosed Lung Cancer, Within Hywel Dda University Health Board Participants Only, Who Were Smokers, Ex-smokers, Never Smoker and Quitters.

Between 2010-2020, the LungCAst observational study followed 3700 patients newly diagnosed with lung cancer across 33 hospitals in Wales and England for 2 years to see if smoking status at time of diagnosis predicted survival rate. This research was sponsored and led by Hywel Dda University Health Board (HDUHB).

This new study examines the health records, (of only the HDUHB participants included in the original LungCAst study), over a longer period of time to see if the benefits of stopping smoking at point of diagnosis with lung cancer continues over a longer period of time (5 years+).

Study Overview

Status

Completed

Conditions

Detailed Description

A study into longer-term outcomes from the LUNGCAST study: comparing survival and healthcare utilisation according to smoking status in people with lung cancer, beyond 2 years. By obtaining Hospital Episode Statistics (HES) extract from the Welsh Patient Administration System (WPAS) and Welsh Clinical Portal (WCP) the investigators can retrospectively follow the cohort participants over time and analyse health care utilisation activity, using univariate and multivariate analysis on the effect of smoking status on survival. The Kaplan-Meier method, will be used to estimate the probability of survival over time.

Study Type

Observational

Enrollment (Actual)

525

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Kingdom
    • Carmarthenshire
      • Carmarthen, Carmarthenshire, United Kingdom, SA31 3BB
        • Hywel Dda University Health Board

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients from the Hywel Dda University Health Board's (HDUHB) site that participated in the original LungCast study.

Description

Inclusion Criteria:

All patients from the Hywel Dda University Health Board's(HDUHB) site that participated in the original LungCast study

Exclusion Criteria:

  • Individuals that did not participate in the original LungCast study in the HDUHB site.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Diagnosed Lung Cancer
Patients diagnosed with Lung Cancer, with smoking status recorded at time of diagnosis.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of longer-term (5 year+) outcomes (survival) of smokers, ex-smokers and never smokers diagnosed with lung cancer between 2010 and 2020
Time Frame: From date of diagnosis (of having lung cancer) for 5 years
Following participants with lung cancer over a 5 year period, by reviewing ongoing healthcare activity via HES extraction and applying the Kaplan-Meier method, to evaluate if smoking status at diagnosis predicts better survival rates over a longer period of time. Univariate and multivariate analysis on the effect of smoking status on survival will also be applied.
From date of diagnosis (of having lung cancer) for 5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hywel Dda Health Board

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 5, 2024

Primary Completion (Actual)

February 4, 2025

Study Completion (Actual)

May 30, 2025

Study Registration Dates

First Submitted

May 7, 2025

First Submitted That Met QC Criteria

August 11, 2025

First Posted (Actual)

August 17, 2025

Study Record Updates

Last Update Posted (Actual)

August 17, 2025

Last Update Submitted That Met QC Criteria

August 11, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRAS 339817

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lung Cancer - Non Small Cell Squamous

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe